1. Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogene
- Author
-
Juan E. Abrahante, Wilaiwan Durose, Ran Blekhman, Anna Strauss, Patrick Blaney, Timothy K. Starr, Sambhawa Priya, Michael B. Burns, Makayla Maile, Juri Habicht, Stefano R. Hellweg, and Christopher R. Clark
- Subjects
0301 basic medicine ,lcsh:Medicine ,Biology ,Ceramides ,Oxidative Phosphorylation ,Article ,Insertional mutagenesis ,Transcriptome ,03 medical and health sciences ,Mice ,RNA interference ,Cell Line, Tumor ,medicine ,Gene silencing ,Animals ,Humans ,lcsh:Science ,Multidisciplinary ,Oncogene ,lcsh:R ,Cell Cycle ,Cancer ,Membrane Proteins ,Nuclear Proteins ,Oncogenes ,Cell cycle ,medicine.disease ,Xenograft Model Antitumor Assays ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Cancer research ,lcsh:Q ,Transposon mutagenesis ,Colorectal Neoplasms ,Signal Transduction ,Transcription Factors - Abstract
New therapeutic targets for advanced colorectal cancer (CRC) are critically needed. Our laboratory recently performed an insertional mutagenesis screen in mice to identify novel CRC driver genes and, thus, potential drug targets. Here, we define Transmembrane 9 Superfamily 2 (TM9SF2) as a novel CRC oncogene. TM9SF2 is an understudied protein, belonging to a well conserved protein family characterized by their nine putative transmembrane domains. Based on our transposon screen we found that TM9SF2 is a candidate progression driver in digestive tract tumors. Analysis of The Cancer Genome Atlas (TCGA) data revealed that approximately 35% of CRC patients have elevated levels of TM9SF2 mRNA, data we validated using an independent set of CRC samples. RNAi silencing of TM9SF2 reduced CRC cell growth in an anchorage-independent manner, a hallmark of cancer. Furthermore, CRISPR/Cas9 knockout of TM9SF2 substantially diminished CRC tumor fitness in vitro and in vivo. Transcriptome analysis of TM9SF2 knockout cells revealed a potential role for TM9SF2 in cell cycle progression, oxidative phosphorylation, and ceramide signaling. Lastly, we report that increased TM9SF2 expression correlates with disease stage and low TM9SF2 expression correlate with a more favorable relapse-free survival. Taken together, this study provides evidence that TM9SF2 is a novel CRC oncogene.
- Published
- 2018